Hypericin-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemEHypericinCat.No.:HY-N0453CASNo.:548-04-9分⼦式:C₃₀H₁₆O₈分⼦量:504.44作⽤靶点:Apoptosis;InfluenzaVirus;Antibiotic;MonoamineOxidase;

PKC;CytochromeP450;Dopamineβ-hydroxylase;Reverse

Transcriptase;Telomerase作⽤通路:Apoptosis;Anti-infection;NeuronalSignaling;Epigenetics;

TGF-beta/Smad;MetabolicEnzyme/Protease;CellCycle/DNA

Damage储存⽅式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性数据体外实验DMSO:250mg/mL(495.60mM;ultrasonicandwarmingandheatto60°C)MassSolvent1mg5mg10mgConcentration制备储备液1mM1.9824mL9.9120mL19.8240mL5mM0.3965mL1.9824mL3.9648mL10mM0.1982mL0.9912mL1.9824mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存⽅式和期限：-80°C,6months;-20°C,1month。-80°C储存时，请在6个⽉内使⽤，-20°C储存时，请在1个⽉内使⽤。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：(为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶)1/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE1.请依序添加每种溶剂：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:2.08mg/mL(4.12mM);Suspendedsolution;Needultrasonic2.请依序添加每种溶剂：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:2.08mg/mL(4.12mM);Clearsolution;NeedultrasonicBIOLOGICALACTIVITY⽣物活性Hypericin⼀种天然存在于贯叶连翘中的物质。HypericinPKC(蛋⽩激酶C)、MAO(单胺氧化酶)、多巴胺-beta-羟化酶、逆转录酶、端粒酶和CYP(cytochromeP450)的抑制剂。Hypericin具有抗肿瘤、抗病毒和抗抑郁的活性，可诱导细胞凋亡。体外研究Hypericin(0.25-4μM;24h)inhibitsthegrowthoffibroblasts(Fb),melanocytes(Mc),andkeratinocytes(Kc)[2].Hypericin(3μM;24h)treatmentcaninducecellsapoptosis[2].CellViabilityAssay[2]CellLine:Fibroblasts(Fb),melanocytes(Mc),andkeratinocytes(Kc)Concentration:0.25μM;0.5μM;1μM;2μM;3μM;4μMIncubationTime:24hoursResult:ShowedtheLD50forFbandMcat1.75μMand3.5μM,respectively,andforKcatagreaterdosethan4μM.ApoptosisAnalysis[2]CellLine:Fibroblasts(Fb),melanocytes(Mc),andkeratinocytes(Kc)Concentration:3μMIncubationTime:24hoursResult:Showedasignificant(p<0.001)earlyapoptoticFbpopulation(64%),andasmaller,significant(p<0.05)earlyapoptoticMcpopulation(20%).体内研究Hypericin(Intravenousinjection;10mg/kg;once)treatmentdelaystumorgrowth[3].AnimalModel:18-20week-oldfemaleBALB/cmiceinjectedwithCT26carcinomas[3]Dosage:10mg/kgAdministration:Intravenousinjection;10mg/kg;onceResult:Showedafourtimesdelayedtumorgrowthcomparedtothecontrolgroups.2/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE户使⽤本产品发表的科研⽂献•Cancers(Basel).2022Mar19;14(6):1575.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].AKubin,etal.Hypericin--thefactsaboutacontroversialagent.CurrPharmDes.2005;11(2):233-53.[2].APopovic,etal.DifferentialsusceptibilityofprimaryculturedhumanskincellstohypericinPDTinaninvitromodel.JPhotochemPhotobiolB.2015Aug;149:249-56.[3].RenataSanovic,etal.Lowdosehypericin-PDTinducescompletetumorregressioninBALB/cmicebearingCT26coloncarcinoma.PhotodiagnosisPhotodynTher.2011Dec;8(4):291-6.McePdfHeightCaution:Producthasnotbeenfullyv